FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:701-711 August 18, 2005 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Soft-tissue sarcomas are uncommon tumors that have traditionally been managed by wide excisional surgery and radiotherapy; the use of chemotherapy has been reserved for advanced disease. Advances in multidisciplinary care have improved the evaluation and care of patients with this disease. Limb-conserving surgical paradigms, superior radiotherapy delivery, and novel adjuvant agents for specific tumors are now available. This overview is intended as a review of current understanding and treatment of soft-tissue sarcoma, with an emphasis on recent advances.

Although soft-tissue sarcomas can arise anywhere in the body (Table 1), the majority occur in the limb or limb girdle . . . [Full Text of this Article]

Demographic and Etiologic Characteristics

Clinical Features, Role of Imaging, and Diagnosis

Pathological Features

Treatment

Surgery

Radiotherapy

Chemotherapy

Targeted Molecular Therapy

Follow-up

Options for Advanced Disease

Conclusions

Source Information

From the Sarcoma Unit, the Royal Marsden Hospital National Health Service Foundation Trust, London.

Address reprint requests to Mr. Clark at the Department of General Surgery, Middlemore Hospital, P.O. Box 93311 Otahuhu, Auckland, New Zealand, or at sarcoma@mac.com.

Related Letters:

Soft-Tissue Sarcoma
Geisinger K. R., Ward W. G., Levine E. A., Clark M. A., Fisher C., Thomas J. M.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:2303-2304, Nov 24, 2005. Correspondence

This article has been cited by other articles:

• Masciullo, V., Berardengo, E., Boglione, A., Sgambato, A., Bernardi, A., Forni, M., Linari, A., Cito, L., Scambia, G., Comandone, A., Giordano, A. (2008). The Retinoblastoma Family Member pRb2/p130 Is an Independent Predictor of Survival in Human Soft Tissue Sarcomas. Clin. Cancer Res. 14: 4775-4779 [Abstract] [Full Text]  
• Guo, Y., Xie, J., Rubin, E., Tang, Y.-X., Lin, F., Zi, X., Hoang, B. H. (2008). Frzb, a Secreted Wnt Antagonist, Decreases Growth and Invasiveness of Fibrosarcoma Cells Associated with Inhibition of Met Signaling. Cancer Res. 68: 3350-3360 [Abstract] [Full Text]  
• Ren, W., Korchin, B., Zhu, Q.-S., Wei, C., Dicker, A., Heymach, J., Lazar, A., Pollock, R. E., Lev, D. (2008). Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth In vitro and In vivo. Clin. Cancer Res. 14: 2785-2795 [Abstract] [Full Text]  
• Ambrosini, G., Cheema, H. S., Seelman, S., Teed, A., Sambol, E. B., Singer, S., Schwartz, G. K. (2008). Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Molecular Cancer Therapeutics 7: 890-896 [Abstract] [Full Text]  
• Ray-Coquard, I., Le Cesne, A., Whelan, J. S., Schoffski, P., Bui, B. N., Verweij, J., Marreaud, S., van Glabbeke, M., Hogendoorn, P., Blay, J.-Y. (2008). A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens. The Oncologist 13: 467-473 [Abstract] [Full Text]  
• Hannay, J. A.F., Liu, J., Zhu, Q.-S., Bolshakov, S. V., Li, L., Pisters, P. W.T., Lazar, A. J.F., Yu, D., Pollock, R. E., Lev, D. (2007). Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Molecular Cancer Therapeutics 6: 1650-1660 [Abstract] [Full Text]  
• Blay, J.-Y., Le Cesne, A., Ray-Coquard, I., Bui, B., Duffaud, F., Delbaldo, C., Adenis, A., Viens, P., Rios, M., Bompas, E., Cupissol, D., Guillemet, C., Kerbrat, P., Fayette, J., Chabaud, S., Berthaud, P., Perol, D. (2007). Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group. JCO 25: 1107-1113 [Abstract] [Full Text]  
• Secondino, S., Carrabba, M. G., Pedrazzoli, P., Castagna, L., Spina, F., Grosso, F., Bertuzzi, A., Bay, J.-O., Siena, S., Corradini, P., Niederwieser, D., Demirer, T., on behalf of the European Group for Blood and Marr, (2007). Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. haematol 92: 418-420 [Abstract] [Full Text]  
• Kleinerman, R. A., Tucker, M. A., Abramson, D. H., Seddon, J. M., Tarone, R. E., Fraumeni, J. F. Jr (2007). Risk of Soft Tissue Sarcomas by Individual Subtype in Survivors of Hereditary Retinoblastoma. JNCI J Natl Cancer Inst 99: 24-31 [Abstract] [Full Text]  
• Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M. G., Ladanyi, M., Miller, V. A., Pao, W. (2006). Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors.. Clin. Cancer Res. 12: 6494-6501 [Abstract] [Full Text]  
• Liu, J., Zhan, M., Hannay, J. A.F., Das, P., Bolshakov, S. V., Kotilingam, D., Yu, D., Lazar, A. F., Pollock, R. E., Lev, D. (2006). Wild-type p53 Inhibits Nuclear Factor-{kappa}B-Induced Matrix Metalloproteinase-9 Promoter Activation: Implications for Soft Tissue Sarcoma Growth and Metastasis. Mol Cancer Res 4: 803-810 [Abstract] [Full Text]  
• Zhang, L., Hannay, J. A.F., Liu, J., Das, P., Zhan, M., Nguyen, T., Hicklin, D. J., Yu, D., Pollock, R. E., Lev, D. (2006). Vascular Endothelial Growth Factor Overexpression by Soft Tissue Sarcoma Cells: Implications for Tumor Growth, Metastasis, and Chemoresistance.. Cancer Res. 66: 8770-8778 [Abstract] [Full Text]  
• Ghert, M. A., Davis, A. M., Griffin, A. M., Alyami, A. H., White, L., Kandel, R. A., Ferguson, P., O'Sullivan, B., Catton, C. N., Lindsay, T., Rubin, B., Bell, R. S., Wunder, J. S. (2005). The Surgical and Functional Outcome of Limb-Salvage Surgery With Vascular Reconstruction for Soft Tissue Sarcoma of the Extremity. Ann. Surg. Oncol. 12: 1102-1110 [Abstract] [Full Text]  
• Geisinger, K. R., Ward, W. G., Levine, E. A., Clark, M. A., Fisher, C., Thomas, J. M. (2005). Soft-Tissue Sarcoma.. NEJM 353: 2303-2304 [Full Text]  
• Fayette, J., Coquard, I. R., Alberti, L., Ranchere, D., Boyle, H., Blay, J.-Y. (2005). ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas. The Oncologist 10: 827-832 [Abstract] [Full Text]